Equillium, Inc. (EQ)

Market Cap	21.54M
Revenue (ttm)	45.91M
Net Income (ttm)	-4.62M
Shares Out	35.43M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,772
Open	0.580
Previous Close	0.600
Day's Range	0.580 - 0.614
52-Week Range	0.560 - 3.250
Beta	1.78
Analysts	Buy
Price Target	5.00 (+722.37%)
Earnings Date	Nov 13, 2024

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: EQ
• Website: https://www.equilliumbio.com

Financial Performance

In 2023, Equillium's revenue was $36.08 million, an increase of 128.97% compared to the previous year's $15.76 million. Losses were -$13.34 million, -78.64% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for EQ stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 722.37% from the latest price.

Price Target

$5.0

(722.37% upside)

Analyst Consensus: Buy